Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 5/2007

01.05.2007 | Original article

Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence

verfasst von: Torun Engfeldt, Anna Orlova, Thuy Tran, Alexander Bruskin, Charles Widström, Amelie Eriksson Karlström, Vladimir Tolmachev

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Expression of human epidermal growth factor receptor type 2 (HER2) in malignant tumours possesses well-documented prognostic and predictive value. Non-invasive imaging of expression can provide valuable diagnostic information, thereby influencing patient management. Previously, we reported a phage display selection of a small (about 7 kDa) protein, the Affibody molecule ZHER2:342, which binds HER2 with subnanomolar affinity, and demonstrated the feasibility of targeting of HER2-expressing xenografts using radioiodinated ZHER2:342. The goal of this study was to develop a method for 99mTc labelling of ZHER2:342 using the MAG3 chelator, which was incorporated into ZHER2:342 using peptide synthesis, and evaluate the targeting properties of the labelled conjugate.

Methods

MAG3-ZHER2:342 was assembled using Fmoc/tBu solid phase peptide synthesis. Biochemical characterisation of the agent was performed using RP-HPLC, ESI-MS, biosensor studies and circular dichroism. A procedure for 99mTc labelling in the presence of sodium/potassium tartrate was established. Tumour targeting was evaluated by biodistribution study and gamma camera imaging in xenograft-bearing mice. Biodistribution of 99mTc-MAG3-ZHER2:342 and 125I-para-iodobenzoate -ZHER2:342 was compared 6 h p.i.

Results

Synthetic MAG3-ZHER2:342 possessed an affinity of 0.2 nM for HER2 receptors. The peptide was labelled with 99mTc with an efficiency of about 75–80%. Labelled 99mTc-MAG3-ZHER2:342 retained capacity to bind specifically HER2-expressing SKOV-3 cells in vitro. 99mTc-MAG3-ZHER2:342 showed specific tumour targeting with a contrast similar to a radioiodinated analogue in mice bearing LS174T xenografts. Gamma camera imaging demonstrated clear and specific visualisation of HER2 expression.

Conclusion

Incorporation of a mercaptoacetyl-containing chelating sequence during chemical synthesis enabled site-specific 99mTc labelling of the ZHER2:342 Affibody molecule with preserved targeting capacity.
Literatur
1.
Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer. Int J Oncol 2000;16:567–76.PubMed
2.
Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004;90:2344–8.CrossRefPubMedPubMedCentral
3.
Gardmark T, Wester K, de la Torre M, Carlsson J, Malmstrom PU. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int 2005;95:982–6.CrossRefPubMed
4.
Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260–6.CrossRefPubMed
5.
Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361–70.CrossRefPubMed
6.
Allred DC, Clark GM, Elledge R, Fugua SA, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200–6.CrossRefPubMed
7.
Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10:1049–56.CrossRefPubMed
8.
Giai M, Roagna R, Ponzone R, De Bortoli M, Dati C, Sismondi P. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 1994;14:1441–50.PubMed
9.
Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359–65.CrossRefPubMed
10.
Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, et al. American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865–78.CrossRefPubMed
11.
12.
De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D, et al. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 1992;52:1916–23.PubMed
13.
Xu FJ, Yu YH, Bae DS, Zhao XG, Slade SK, Boyer CM, et al. Radioiodinated antibody targeting of the HER-2/neu oncoprotein. Nucl Med Biol 1997;24:451–9.CrossRefPubMed
14.
Zalutsky MR, Xu FJ, Yu Y, Foulon CF, Zhao XG, Slade SK, et al. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. Nucl Med Biol 1999;26:781–90.CrossRefPubMed
15.
Tsai SW, Sun Y, Williams LE, Raubitschek AA, Wu AM, Shively JE. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. Bioconjug Chem 2000;11:327–34.CrossRefPubMed
16.
Garmestani K, Milenic DE, Plascjak PS, Brechbiel MW. A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. Nucl Med Biol 2002;29:599–606.CrossRefPubMed
17.
Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, et al. Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol 2004;143:99–106.CrossRefPubMedPubMedCentral
18.
Persson M, Gedda L, Jensen HJ, Lundqvist H, Malmström P-U, Tolmachev V. Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2 expressing tumors. Oncol Rep 2006;15:673–80.PubMed
19.
Persson M, Tolmachev V, Andersson K, Gedda L, Sandström M, Carlsson J. [177Lu]pertuzumab. Experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging 2005;32:1457–62.CrossRefPubMed
20.
Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 2002;13:603–8.CrossRefPubMed
21.
Britz-Cunningham SH, Adelstein J. Molecular targeting with radionuclides: state of the science. J Nucl Med 2003;44:1945–61.PubMed
22.
Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS, Stafford WF 3rd, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993;53:4026–34.PubMed
23.
Olafsen T, Tan GJ, Cheung CW, Yazaki PJ, Park JM, Shively JE, et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 2004;17:315–23.CrossRefPubMed
24.
Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22:701–6.CrossRefPubMed
25.
Tang Y, Wang J, Scollard DA, Mondal H, Holloway C, Kahn HJ, et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastusumab (Herceptin) Fab fragments. Nucl Med Biol 2005;32:51–8.CrossRefPubMed
26.
Nord K, Gunneriusson E, Ringdahl J, Ståhl S, Uhlén M, Nygren PÅ. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 1997;15:772–7.CrossRefPubMed
27.
Nord K, Gunneriusson E, Uhlén M, Nygren PÅ. Ligands selected from combinatorial libraries of protein A for use in affinity capture of apolipoprotein A-1M and taq DNA polymerase. J Biotechnol 2000;80:45–54.CrossRefPubMed
28.
Rönnmark J, Hansson M, Nguyen T, Uhlén M, Robert A, Ståhl S, et al. Construction and characterization of affibody-Fc chimeras produced in Escherichia coli. J Immunol Methods 2002;261:199–211.CrossRefPubMed
29.
Rönnmark J, Kampf C, Asplund A, Höiden-Guthenberg I, Wester K, Ponten F, et al. Affibody-beta-galactosidase immunoconjugates produced as soluble fusion proteins in the Escherichia coli cytosol. J Immunol Methods 2003;281:149–60.CrossRefPubMed
30.
Renberg B, Shiroyama I, Engfeldt T, Nygren PK, Karlström AE Affibody protein capture microarrays: synthesis and evaluation of random and directed immobilization of affibody molecules. Anal Biochem 2005;341:334–43.CrossRefPubMed
31.
Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, et al. Selection and characterisation of HER2/neu-binding affibody ligands. Protein Eng Des Sel 2004;17:455–62.CrossRefPubMed
32.
Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson F, Ståhl S, et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide based diagnostics. Cancer Biother Radiopharm 2005;20:239–48.CrossRefPubMed
33.
Steffen AC, Orlova A, Wikman M, Nilsson FY, Stahl S, Adams GP, et al. Affibody mediated tumor targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging 2006;33:631–8.CrossRefPubMed
34.
Mume E, Orlova A, Nilsson F, Larsson B, Nilsson AS, Sjöberg S, et al. Evaluation of (4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjugate Chem 2005;16:1547–55.CrossRef
35.
Orlova A, Magnusson M, Eriksson T, Nilsson M, Larsson B, Höiden-Guthenberg I, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006;66:4339–48.CrossRefPubMed
36.
Tolmachev V, Nilsson FY, Widström C, Andersson K, Gedda L, Wennborg A, et al. 111In-benzyl-DTPA-ZHER2:342, an Affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 2006;47:846–53.PubMed
37.
Orlova A, Nilsson F, Magnusson M, Gedda L, Widstrom C, Wennborg A, et al. 111In-Bz-DTPA-ZHER2:342, a candidate for imaging of HER2-expression in malignant tumors. J Lab Comp Radiopharm 2005;48 Suppl 1:S51.
38.
Liu S, Edwards DS. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 1999;99:2235–68.CrossRefPubMed
39.
Orlova A, Nilsson F, Wikman M, Ståhl S, Carlsson J, Tolmachev V. Comparative in vivo evaluation of iodine and technetium labels on anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med 2006;47:512–9.PubMed
40.
Zhu Z, Wang Y, Zhang Y, Liu G, Liu N, Rusckowski M, et al. A novel and simplified route to the synthesis of N3S chelators for 99mTc labeling. Nucl Med Biol 2001;28:703–8.CrossRefPubMed
41.
Qu T, Wang Y, Zhu Z, Rusckowski M, Hnatowich DJ. Different chelators and different peptides together influence the in vitro and mouse in vivo properties of 99Tcm. Nucl Med Commun 2001;22:203–15.CrossRefPubMed
42.
Lei K, Rusckowski M, Chang F, Qu T, Mardirossian G, Hnatowich DJ. Technetium-99m antibodies labeled with MAG3 and SHNH: an in vitro and animal in vivo comparison. Nucl Med Biol 1996;23:917–22.CrossRefPubMed
43.
Kim MK, Jeong HJ, Kao CH, Yao Z, Paik DS, Pie JE, et al. Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications. Nucl Med Biol 2002;29:139–46.CrossRefPubMed
44.
Kobayashi H, Yoo TM, Kim IS, Kim MK, Le N, Webber KO, et al. L-Lysine effectively blocks renal uptake of I-125 or Tc-99m labeled anti-Tac disulfide-stabilized Fv fragment. Cancer Res 1996;56:3788–95.PubMed
45.
Decristoforo C, Mather SJ. Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide. Bioconjugate Chem 1999;10:431–8.CrossRef
46.
Zhang YM, Liu N, Zhu ZH, Rusckowski M, Hnatowich DJ. Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA. Eur J Nucl Med 2000;27:1700–7.CrossRefPubMed
47.
Engfeldt T, Renberg B, Brumer H, Nygren PÅ, Karlström AE. Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein. Chembiochem 2005;6:1043–50.CrossRefPubMed
48.
Blok D, Feitsma HI, Kooy YM, Welling MM, Ossendorp F, Vermeij P, et al. New chelation strategy allows for quick and clean 99mTc-labeling of synthetic peptides. Nucl Med Biol 2004;31:815–20.CrossRefPubMed
49.
Winnard P Jr, Chang F, Rusckowski M, Mardirossian G, Hnatowich DJ. Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA. Nucl Med Biol 1997;24:425–32.CrossRefPubMed
50.
Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004;10:7834–41.CrossRefPubMed
51.
Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, et al. α-Particle radioimmunotherapy of disseminated peritoneal disease using a 212Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 2005;20:557–68.CrossRefPubMed
52.
Orlova A, Bruskin A, Sjöström A, Lundqvist H, Gedda L, Tolmachev V. Cellular processing of 125I and 111In labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. Nucl Med Biol 2000;27:827–35.CrossRefPubMed
53.
Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, et al. A single treatment of yttrium-90-labeled CHX-A″-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 2004;64:6200–6.CrossRefPubMed
54.
Behr TM, Gotthardt M, Barth A, Behe M. Imaging tumors with peptide-based radioligands. Q J Nucl Med 2001;45:189–200.PubMed
55.
Hnatowich DJ, Chang F, Lei K, Ruscowski M. The influence of temperature and alkaline pH on the labeling of free and conjugated MAG3 with technetium-99m. Appl Radiat lsot 1997;48:587–94.CrossRef
56.
Wegener WA, Petrelli N, Serafini A, Goldenberg DM. Safety and efficacy of arcitumomab imaging in colorectal cancer after repeated administration. J Nucl Med 2000;41:1016–20.PubMed
57.
Fuster D, Maurel J, Muxi A, Setoain X, Ayuso C, Martin F, et al. Is there a role for 99mTc-anti-CEA monoclonal antibody imaging in the diagnosis of recurrent colorectal carcinoma? Q J Nucl Med 2003;47:109–15.PubMed
Metadaten
Titel
Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence
verfasst von
Torun Engfeldt
Anna Orlova
Thuy Tran
Alexander Bruskin
Charles Widström
Amelie Eriksson Karlström
Vladimir Tolmachev
Publikationsdatum
01.05.2007
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-006-0266-4

Weitere Artikel der Ausgabe 5/2007

European Journal of Nuclear Medicine and Molecular Imaging 5/2007 Zur Ausgabe

Original Article

Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

Image of the month

Tumour thrombus in the superior vena cava from anaplastic carcinoma of the thyroid: FDG-PET/CT imaging findings

Original article

Indium-111 oxine labelling affects the cellular integrity of haematopoietic progenitor cells

Short Communication

In vivo assessment of [11C]MRB as a prospective PET ligand for imaging the norepinephrine transporter

Editorial

Is a methodology available that accurately measures the cost of an FDG-PET study?

Review article

Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”